Los Angeles Capital Management
PRTK

Los Angeles Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Los Angeles Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,318
Closed -$275K – 1622
2021
Q2 		$275K Buy
40,318
+23,406
+138% +$189K ﹤0.01% 1422
2021
Q1 		$119K Sell
16,912
-15,587
-48% -$112K ﹤0.01% 1565
2020
Q4 		$203K Buy
+32,499
New +$191K ﹤0.01% 1469
2018
Q3 		– Sell
-61,486
Closed -$627K – 1514
2018
Q2 		$627K Buy
+61,486
New +$696K ﹤0.01% 1072

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Los Angeles Capital Management's PRTK Position: Q3 2021 in Review

Los Angeles Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2021, closing a stake of 40,318 shares — an estimated $275K sold.

Los Angeles Capital Management first reported a position in PRTK in Q2 2018 and held it in 4 quarters. The position peaked at $627K in Q2 2018. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2021.

  • Los Angeles Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Los Angeles Capital Management sold 40,318 Paratek Pharmaceuticals, Inc. shares in Q3 2021, an estimated $275K.
  • Los Angeles Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2018 and held it in 4 quarters.
  • Los Angeles Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $627K in Q2 2018.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2021.

Based on Los Angeles Capital Management's 13F filing for Q3 2021, filed 5 Nov 2021.